Bayer's stock (BAYRY) has experienced
considerable volatility amidst various factors. After five years of losses, the company displayed a
45% rally in 2025, and further soars as its earnings release draws closer. Despite quarterly losses and setbacks in litigation,
Bayer's Q2 earnings beat expectations, pushing its share prices up. However, a court order necessitating the payment of $2B in a litigation case saw the company's stocks slump. Looking towards the future, Bayer pins growth prospects to FY26. The company’s stocks have been gaining due to an increased
2025 outlook. In addition, its stocks won an upgrade to a 'Buy' rating from Goldman Sachs based on Bayer’s positive outlook. However, fearing inflation in earnings, some investors have voiced concerns. Despite some turbulence, including a
drop in Q1 earnings and a $2.1 billion Roundup cancer verdict, Bayer records strong demand for its cancer drugs which has increased shares by over 5%. Additionally, winning the FDA’s approval for expanding the label of
Kerendia in heart failure will likely also favor the company.
BAYER Stocks News Analytics from Tue, 12 Nov 2024 08:00:00 GMT to Wed, 10 Sep 2025 10:24:28 GMT -
Rating 8
- Innovation 7
- Information 8
- Rumor -5
